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Zygote arrest (Zar) proteins are crucial for early embryonic development, but their molecular
mechanism of action is unknown. The Translational Control Sequence (TCS) in the 30 untranslated
region (UTR) of the maternal mRNA, Wee1, mediates translational repression in immature Xenopus
oocytes and translational activation in mature oocytes, but the protein that binds to the TCS and
mediates translational control is not known. Here we show that Xenopus laevis Zar2 (encoded by zar2)
binds to the TCS in maternal Wee1 mRNA and represses translation in immature oocytes. Using yeast
3 hybrid assays and electrophoretic mobility shift assays, Zar2 was shown to bind speciﬁcally to the TCS
in the Wee1 30UTR. RNA binding required the presence of Zn2þ and conserved cysteines in the
C-terminal domain, suggesting that Zar2 contains a zinc ﬁnger. Consistent with regulating maternal
mRNAs, Zar2 was present throughout oogenesis, and endogenous Zar2 co-immunoprecipitated
endogenous Wee1 mRNA from immature oocytes, demonstrating the physiological signiﬁcance of
the protein–RNA interaction. Interestingly, Zar2 levels decreased during oocyte maturation. Dual
luciferase reporter tethered assays showed that Zar2 repressed translation in immature oocytes.
Translational repression was relieved during oocyte maturation and this coincided with degradation of
Zar2 during maturation. This is the ﬁrst report of a molecular function of zygote arrest proteins. These
data show that Zar2 contains a zinc ﬁnger and is a trans-acting factor for the TCS in maternal mRNAs in
immature Xenopus oocytes.
& 2012 Elsevier Inc. All rights reserved.Introduction
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ity of Leicester, Leicester, UK.embryo after fertilization and prior to zygotic genome activation
(Farley and Ryder, 2008). Maternal effect genes were ﬁrst char-
acterized in Drosophila in the 1980s, but mammalian maternal
effect genes were not described until 2000 (Li et al., 2010). One of
the earliest mammalian maternal effect factors reported, Zygote
arrest 1 (Zar1) (Wu et al., 2003a), was found in a subtractive
hybridization screen to identify mammalian maternal acting
genes. Female mice null for Zar1 are infertile because embryogen-
esis is blocked at the 1-cell stage. Since then, Zar1 has been
identiﬁed in many vertebrate species from frogs to humans
(Brevini et al., 2004; Michailidis et al., 2010; Uzbekova et al.,
2006; Wu et al., 2003b). A sequence related to Zar1 has also been
identiﬁed in many vertebrates, and called Zar2 (Xzar2 in Xenopus
laevis) or Zar1-like/Zar1l (Hu et al., 2010; Michailidis et al., 2010;
Misra et al., 2010; Nakajima et al., 2009; Sangiorgio et al., 2008).
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sion of embryogenesis. Zar1 has been implicated in completion of
fertilization, activation of the zygotic genome and progression
past the 1-cell stage in mouse embryos (Wu et al., 2003a), and
Zar2 (aka Zar1l) has been implicated in epidermalization of
Xenopus embryos and progression past the 2-cell stage in mouse
embryos (Hu et al., 2010; Nakajima et al., 2009). Zar1 and Zar2
transcripts are predominantly expressed in ovary and testis, with
the highest levels in immature (germinal vesicle) oocytes (Brevini
et al., 2004; Hu et al., 2010; Michailidis et al., 2010; Pennetier
et al., 2004; Sangiorgio et al., 2008; Uzbekova et al., 2006; Wu
et al., 2003a; Wu et al., 2003b). Zar1 and Zar2 transcripts decline
by the 2-cell stage in mouse embryos (Hu et al., 2010; Wu et al.,
2003b), the 8-cell stage in pig embryos (Uzbekova et al., 2006),
the blastocyst stage in bovine embryos (Brevini et al., 2004), and
gastrulation in Xenopus embryos (Nakajima et al., 2009; Wu et al.,
2003b). In the chick embryo, Zar1 and Zar2 transcripts are
expressed for at least 7 days (Michailidis et al., 2010). Thus,
Zar1 and Zar2 likely play a role in early zygotic development in
many vertebrate species.
Zar1 and Zar2 share a highly conserved C-terminal domain
with invariably conserved cysteines across all vertebrates
sequenced to date, which has led to the suggestion that Zar1
and Zar2 contain zinc ﬁngers that regulate transcription. Indeed,
Zar1 is implicated in activation of the zygotic genome (Wu et al.,
2003a), and Zar2 is implicated in RNA synthesis, histone methyla-
tion and expression of nuclear reprogramming factors (Hu et al.,
2010). However, Zar1 and Zar2 have also been shown to localize
to the cytoplasm in mouse oocytes and embryos, and speciﬁcally
to P-bodies, suggesting a role for Zar proteins in RNA metabolism
(Hu et al., 2010; Misra et al., 2010; Wu et al., 2003a). While it is
clear that Zar1 and Zar2 have important roles in early develop-
ment, their molecular mechanism of action is still unclear.
Translational control of maternal mRNAs is critical to the
developing zygote prior to genomic activation (Farley and
Ryder, 2008). A plethora of developmentally regulated cis ele-
ments in the 30 untranslated regions of mRNAs determine where,
when and to what extent an mRNA is translated (Colegrove-Otero
et al., 2005; MacNicol and MacNicol, 2010). In vertebrate meiosis,
mRNA translation is often correlated with elongation of the
poly(A) tail in a process called cytoplasmic polyadenylation
(Villalba et al., 2011). Polyadenylation and translation of maternal
Wee1 mRNA occur after the ﬁrst meiotic metaphase in maturing
Xenopus oocytes (Charlesworth et al., 2000). The resulting Wee1
protein is implicated in the lengthening of the ﬁrst embryonic
mitotic cell cycle (Murakami et al., 1999; Murakami and Vande
Woude, 1998) and in morphogenesis at gastrulation (Murakami
et al., 2004). Wee1 mRNA translation is under the control of at
least two different types of cis elements in the 30 UTR, the
cytoplasmic polyadenylation element (CPE) and the newly
described Translational Control Sequence (TCS) (Charlesworth
et al., 2000; Wang et al., 2008). Both CPEs and TCSs repress
translation in immature oocytes and stimulate translation in
mature oocytes. Whereas the mechanism of translational regula-
tion by CPEs is well documented and is mediated by CPE-binding
protein (CPEB) (Villalba et al., 2011), the mechanism of transla-
tional regulation by TCSs has yet to be described and the
protein(s) that binds to the TCS has yet to be identiﬁed.
In a previous study (Charlesworth et al., 2006), we isolated two
proteins in a screen to identify the trans-acting factor that bound
to a new cis-element, the polyadenylation response element
(Charlesworth et al., 2002), now referred to as the Musashi
binding element (MBE) (Arumugam et al., 2010), in the 30 UTR
of the Mos mRNA. One protein, Musashi (C36), bound to the MBE,
whereas the second protein (A8) did not. Here, we show that A8 is
the C-terminal of Xenopus laevis Zar2 and that it binds to the TCSin the Mos and Wee1 mRNA 30 UTRs via a zinc ﬁnger. Further-
more, we show that Zar2 represses translation in immature
Xenopus oocytes. We propose that Zar2 is a trans-acting factor
for the TCS.Material and methods
Yeast 3 hybrid assay and plasmids
The yeast screen has been described previously (Charlesworth
et al., 2006). Yeast transformations and b-galactosidase expres-
sion colony lift and liquid culture assays were performed as
described in Yeast Protocols Handbook (Clontech). Yeast strains
and plasmids were kindly provided by Dr. Marvin Wickens,
University of Wisconsin, Madison.
All restriction enzymes, Klenow fragment and Quick Ligase
were obtained from New England Biolabs. DNA oligonucleotides
were synthesized by Integrated DNA Technologies.
pACT2-A8 (C-zar2) was isolated from a Xenopus oocyte cDNA
library (Clontech).
pIIIA MS2-2.1 Mos M1 48 has been described previously
(Charlesworth et al., 2006). pIIIA MS2-2.1 Mos WT 48 was made
from pIIIA MS2-2.1 Mos M1 48 using QuikChange. The disrupted
CPE (TTTGGT) was changed back to wild type CPE (TTTtaT). pIIIA
MS2-2.1 Mos DMBE was made from pIIIA MS2-2.1 Mos M1 48
using QuikChange (Stratagene). The disrupted CPE (TTTGGT) was
changed back to TTTtaT and 20 nt of the MBE (ATC CAT ATG TGA
ATA TAT AG) (Charlesworth et al., 2002) were deleted. pIIIA MS2-
2.1 Mos DTCS was made from pIIIA MS2-2.1 Mos M1 48 using
QuikChange by deleting the 7 nt TCS (TTTGTCT).
pIIIA MS2 IRE and pACT2 IRP have been described previously
(Bernstein et al., 2002).
pIIIA 2–2.1 b-globin and pIIIA 2–2.1 b-globin/TCS: PCR primers
were designed to amplify the last 81 bp of the b-globin and the
b-globin/TCS 30 UTR sequence with a 50 XhoI site and a 30 NarI site,
using pGEMGST b-globin and pGEMGST b-globin/TCS (TTTGTCT).
The b-globin 30UTR was ampliﬁed using Platinum Pfx (Invitrogen)
and the PCR product digested with XhoI and NarI, and ligated into
XhoI/NarI digested pIIIA MS2-2.1.
pIIIA MS2-1 Wee WT: pGEM Wee79 EMSA (Charlesworth
et al., 2000) was digested with EcoRI/HindIII, blunted with
Klenow and ligated into pIIIA MS2-1 (Bernstein et al., 2002) that
was digested with SmaI.
pIIIA MS2-2.1 Wee DTCS: QuikChange mutagenesis was also
employed to delete the TCS elements (ATTGTCT and ATTATCT)
within the Wee1 30 UTR to generate Wee1 DTCS.
(Requests for the above plasmids should be made to AMM.)
Cloning of full length zar2b and subsequent plasmids
pENTR zar2b: The 50 end of zar2bwas cloned using First Choice
RLM-RACE Kit (Ambion), according to manufacturer’s directions.
50 RACE was performed on the mRNA from immature oocytes
from two different frogs to ensure the full length 50 end was
identiﬁed. The inner 50RACE primer was 50-GTC GAC TGG CCA
AGG GCT GCG CGA C and the outer primer was 50-GGT AAT CCG
TGG GCT CAG AAG CCT T. EST sequences AW644676, BJ614564
and AW637792 were used to verify the integrity of sequence we
had identiﬁed and support the idea that we have the paralog of
zar2 that was previously reported (Nakajima et al., 2009). Once
the sequence from the 50 end was conﬁrmed, primers were
designed to amplify the full length zar2b, forward primer 50-CAC
CAT GGC GGG CTT TAT GTA TGC GC, reverse primer 50-TCA GAC
GAT GTA CTT GTA GCT GTA AGT GTT GT, using the high ﬁde-
lity Pfu (Stratagene) according to manufacturer0s directions.
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pENTR (Invitrogen). The full length zar2b sequence has been
submitted to Genbank (Genbank ID: JQ776638).
pVL1393-FLAG-C-zar2 for baculovirus protein expression:
pVL1393 (Orbigen) was cut with BamHI/PstI. A duplex encoding
3xFLAG with BamHI and XbaI sites was synthesized (IDT). The
C-terminal 159–307 amino acids were ampliﬁed from pENTR
zar2b, forward primer 50-GCA TCT AGA ATG GCG GGC TTT ATG
TAT GCG and reverse primer, 50-GCT CTG CAG TCA GAC GAT GTA
CTT GTA GCT with XbaI and PstI sites (underlined). The 3xFLAG
and C-zar2 were digested with the appropriate restriction
enzymes and ligated into pVL1393.
pGEX 6P-3 zar2b, pGEX 6P-3 N-zar2 (amino acids 1–158),
pGEX 6P-3 C-zar2 (amino acids 159–307) and cysteine mutants:
Plasmids were made by inserting PCR products from template
pENTR zar2b into pGEX 6P-3 vector (GE Lifesciences). The forward
primer for full length and N-terminus was 50-GAT CGG ATC CAT
GGC GGG CTT TAT GTA T and the reverse primer for full length
was 50-CTA GGT CGA CTC AGA CGA TGT ACT TGT A, and for the
N-terminus was 50-CTA GGT CGA CTC ACT CCT TCA GCG GCT GTG
A, with BamHI and SalI sites (underlined). The forward primer for
C-terminus was 50-CGG GAT CCA GAG CGC CCT CCC CCG AG and
the reverse primer was 50-ATA AGA ATG CGG CCG CTC AGA CGA
TGT ACT TGT AGC, with BamHI and NotI sites (underlined). The
cysteine to alanine mutations were performed by QuikChange
mutagenesis methods with the following codon changes: C215A,
TGC-GCC; C242A, TGT-GCT; C259A, TGC-GCC; C267A, TGC-
GCC; C287A, TGC-GCC.
pXen N-MS2: PCR primers were designed to amplify the MS2
coding sequence from pJC5 (kindly provided by Jeff Coller, Case
Western Reserve University, OH) (Gray et al., 2000) with a 50 NcoI
site and a 30 ClaI site, forward primer 50-GAT CCC ATG GCT TCT
AAC TTT ACT CAG TTC and reverse primer 50-GAT CAT CGA TGC
GTA GAT GCC GGA GTT TGC TGC. Digested PCR product was
ligated into NcoI/ClaI digested pXen1, replacing the GST coding
sequence.
pXen MS2-Xp54: PCR primers were designed to amplify the
Xp54 coding sequence from Xp54 in the MSP vector (Minshall
et al., 2001) (kindly provided by Nancy Standart, University of
Cambridge, UK) with a 50 KpnI site and a 30 BamHI site, forward
primer 50-GAT CGG TAC CCA TGA GCA CCG and reverse primer 50-
GAT CGG ATC CTT AAG GTT TGT. Digested PCR product was
ligated into KpnI/BamHI digested pXen N-MS2.
pXen N-zar2-MS2: pXen1 was digested with NcoI and ClaI to
remove GST coding sequence, then treated with Klenow to blunt
ends and self-ligated make pXen DGST. MS2 coding sequence was
ampliﬁed from pJC5 using primers with a 50 XmaI site and a 30
XbaI site, forward primer 50-CTA GCC CGG GCT ATG GCT TCT AAC
TTT ACT CAG TTC and reverse primer 50-GAT CTC TAG AGT TAG
TAG ATG CCG GAG TTT GCT G. Digested PCR product was then
ligated into XmaI/XbaI digested pXen DGST to make pXen C-MS2.
Amino acids 1–158 of zar2b was ampliﬁed from pENTR-zar2b
with a 50 KpnI site and a 30 BamHI site, forward primer 50-GAT
CGG TAC CAT GGC GGG CTT and reverse primer 50-GAT CGG ATC
CGC TCT CTT CAG, appropriately digested, and ligated into KpnI/
BamHI digested pXen C-MS2.
pXen rluc: PCR primers were designed to amplify Renilla
luciferase (rluc) coding sequence (plasmid kindly provided by
Nancy Standart) with a 50 NcoI site and a 30 ClaI site, forward
primer 50-CAT GCC ATG GCT TCG AAA GTT TAT GAT CCA and
reverse primer 50-GAT CAT CGA TTT ATT GTT CAT TTT TGA GAA
CTC G. Digested PCR product was then ligated into NcoI/ClaI
digested pXen1, replacing the GST coding sequence. This plasmid
was linearized with EcoRI prior to in vitro transcription.
pXen ﬂuc: The ﬁreﬂy luciferase (ﬂuc) coding sequence was
ampliﬁed from JC18 (kindly provided by Jeff Coller) (Gray et al.,2000) using primers with a 50 NcoI site and a 30 XhoI site, forward
primer 50-GAT CCC ATG GAA GAC GCC AAA AAC ATA AAG and
reverse primer 50-GAT CCT CGA GTT ACA ATT TGG ACT TTC CGC C.
The PCR product was inserted into pXen1 using NcoI/XhoI,
replacing the GST coding sequence.
pXen ﬂuc-2x-SL (pXen ﬂuc with stem–loops): An Nde I site
was inserted into the b-globin 30UTR of pXen ﬂuc, 59 nucleotides
upstream of the polyadenylation hexanucleotide, using Quik-
Change site directed mutagenesis (Stratagene) to make pXen
ﬂuc-NdeI. A DNA duplex (IDT) containing the sequence of two
MS2 stem–loops (2 -SL) (Bardwell and Wickens, 1990) with 50
and 30 NdeI sites was digested with NdeI and ligated into NdeI
digested pXen ﬂuc-NdeI. This plasmid was linearized with SacI
prior to in vitro transcription.
All plasmids were sequenced to verify integrity using the
University of Colorado Cancer Center DNA Sequencing and Ana-
lysis Core. Requests for the latter plasmids should be made to AC.
For in vitro transcription, all plasmids were linearized with PstI
unless otherwise noted. 50 capped RNA was synthesized in vitro
with SP6 mMessage mMachine transcription kit (Ambion). RNA
quality was assessed using gel electrophoresis.
Insect cell protein expression and puriﬁcation
FLAG-tagged C-terminus Xenopus Zar2 (FLAG-C- Zar2) protein
was prepared from baculovirus infected Sf9 insect cells. Infections
and cell culture were performed by Lori Sherman, Protein Produc-
tion/Mab/Tissue Culture Core Manger, University of Colorado
Cancer Center. About 3 ml of pelleted cells were suspended in
lysis buffer (50 mM Tris HCl pH 7.7, 150 mM KCl, 0.1% Triton
X-100, complete protease inhibitors (Roche)) and lysed by soni-
cating 20 s twice at 30% output (Virsonic 50, Virtis). After
centrifugation at 14,000 g for 15 min at 4 1C, supernatant was
collected and incubated with 3 ml of anti-FLAG agarose (Sigma)
overnight at 4 1C. Beads were washed with lysis buffer supple-
mented with 0.35 M NaCl for 1.5 h and protein was eluted with
3xFLAG peptide overnight. After quality and quantity of eluate
were checked by SDS-PAGE, protein was concentrated with
Vivaspin2 columns (GE Healthcare) at 5000 g until a concentra-
tion of 0.4 mg/ml was reached.
Bacterial protein expression and puriﬁcation
GST-C-Zar2 protein was puriﬁed from E. coli BL21 (DE3)
(Novagen). The protein expression was induced with 0.5 mM
IPTG overnight at 25 1C. Cell pellets were suspended into GST
lysis buffer (PBS, 0.1% Triton X-100, Complete EDTA-free protease
inhibitor (Roche)) and lysed by sonicating 20 s, 3 times at
30% output (Virsonic 50, Virtis) on ice. After centrifugation,
supernatant was incubated with glutathione sepharose beads
(GE Healthcare) for 1.5 h at room temperature. Beads were
washed with wash buffer (PBS, 0.5 M NaCl, 1% Triton X-100) for
30 min at 4 1C. GST-C-Zar2 was eluted from beads with elution
buffer (20 mM reduced glutathione, 10 mM Tris–HCl pH 8.0,
150 mM NaCl, 1 mM DTT, 0.1% Triton X-100), dialysed against
dialysis buffer (50 mM Tris–HCl pH 7.4, 300 mM NaCl, 1 mM DTT,
0.01% TritonX-100) using Slide-A-Lyzer 10,000 MWCO (Thermo
Scientiﬁc), and concentrated with Vivaspin2 (GE Healthcare). For
the Zn2þ requirement study, 1 mM EDTA was added to lysis and
wash buffers at the time of puriﬁcation, but not to elution or
dialysis buffers.
Electrophoretic mobility shift assays (EMSA)
RNA probes were the last 50 nt of the Wee1 30UTR labeled at
the 50 end with Cy5 (Integrated DNA Technologies) and were heat
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combined with 400–800 ng protein (or as described in ﬁgure
legends) in a 20 ml reaction containing 10 mM HEPES pH 7.7,
100 mM KCl, 1 mM MgCl2, 10 mM DTT, 20 mM ZnCl2, 50 mg/ml
tRNA, 0.1 mg/ml BSA, 5% glycerol, 0.25% NP40 and incubated
20 min at room temperature. 0.5 ml of heparin (200 mg/ml) was
added for a further 20 min. 5 ml of 5 loading buffer (0.15 g/ml
Ficoll 400, 0.25% Orange G, 1xTBE) was added to the binding
reaction and 5 ml of this loaded onto a 6% RNA retardation gel
(Novex, Invitrogen). Gels were run according to manufacturer0s
instructions. For the Zn2þ requirement study, ZnCl2 was elimi-
nated from the binding buffer. Anti-FLAG (Sigma) and anti-C-Zar2
antibodies used for the supershift assay were added for the last
10 min of the binding reaction. For competition assays, proteins
were preincubated for 20 min at room temperature with unla-
beled RNA (IDT). The gel was imaged directly with the Odyssey
(LiCor) in the 700 nm channel.
Oocyte isolation, culture and microinjection
Adult female Xenopus laevis were housed and sacriﬁced
according to internationally recognized guidelines and with the
approval of the University of Colorado Denver Institutional
Animal Care and Use Committee. Xenopus laevis (Nasco) oocytes
were isolated and cultured as has been described (Machaca and
Haun, 2002). All incubations were carried out in 0.5 L-15
(MediaTech, Inc.) with penicillin (100 mg/ml) and streptomycin
(50 mg/ml). Dumont stage VI (Dumont, 1972) oocytes were
selected and injected with 23 nl of the appropriate MS2 fusion
mRNA: approximately 1 ng of MS2, 20 ng of MS2-Xp54, and 5 ng,
20 ng or 50 ng of N-zar2-MS2. Oocytes were incubated overnight
(16 h) at 18 1C, then injected with 100 pg of ﬂuc-2 -SL or
ﬂuc mRNA, together with 5 pg of rluc mRNA as a loading
control, in 23 nl of nuclease free water. Injections were performed
using a Drummond NanoInject II microinjector, and media was
supplemented with 2.5% Ficoll 400 during injections. Appropriate
samples were then induced to mature with 2 mM progesterone
and all samples were collected 2–3 h after progesterone treated
samples underwent GVBD, as indicated by the appearance of a
white spot. Immature samples were time-matched to progester-
one-treated samples (11 h after luciferase injection).
Luciferase assay and statistical analysis
Two pools of 5 oocytes were collected from each sample and
lysed in duplicate in 50 ml/oocyte of Passive Lysis Buffer (Pro-
mega). A 10 ml portion of cleared lysate was analyzed using the
Dual-Luciferase Reporter Assay System (DLR) (Promega) on a
Synergy HT plate reader (BioTek). The ratio of ﬁreﬂy to Renilla
luciferase activity (DLR ratio) was calculated for each experimen-
tal point. The mean DLR ratio was calculated for immature oocyte
samples injected with MS2 alone and all immature samples were
normalized to this value, resulting in MS2 alone values being
arbitrarily set to 1 and all other values being expressed as a
change in translation relative to MS2 alone. Progesterone-treated
samples were similarly normalized to the mean value of proges-
terone-treated MS2 alone. This experiment was performed inde-
pendently with the same parameters on multiple frogs (n¼4–5)
and normalized results were pooled. One-way analysis of var-
iance and post hoc Bonferroni multiple comparison test were
performed using GraphPad Prism 5 software to analyze difference
among the means of the normalized results. Differences with P-
value less than 0.01 were considered statistically signiﬁcant.
Additionally, a Mann–Whitney U test was performed to analyze
differences among medians of the normalized results with similar
results.Western blot
Pools of 10 oocytes were collected from each sample and lysed
in 10 ml/oocyte of NP-40 lysis buffer (1% Igepal CA-630, 20 mM
Tris pH 8.0, 137 mM NaCl, 10% glycerol, 2 mM EDTA) supplemen-
ted with protease and phosphatase inhibitors (HALT, Pierce). 5 or
10 ml of cleared lysate (0.5 or 1 oocyte equivalent respectively)
was loaded onto a NuPage 4–12% Bis-Tris polyacrylamide gel
(Novex). For stages I–VI and in vitro matured oocytes, oocytes
were lysed in NP-40 lysis buffer and total protein amount was
measured by BCA protein assay kit (Pierce). 3.75 mg total protein
per lysate was loaded onto the gel. Electrophoresis was performed
using MOPS-SDS running buffer (Invitrogen), then transferred to
0.45 mm Immobilon-FL PVDF membrane (Millipore) using an
XCell II Blot Module (Invitrogen) according to NuPage technical
guide protocol. Membranes were probed with MS2 antibody
(TetraCore), GST antibody (Santa Cruz Biotechnology), b-Tubulin
antibody (Sigma), or Zar2 antibodies (Charlesworth). Secondary
antibodies were 1:20,000 IR Goat anti-rabbit IR Dye 800 CW and
Goat anti-mouse IR Dye 680LT (LiCor). Membranes were imaged
on an Odyssey infrared imager and data was analyzed using
Odyssey 2.1 software (LiCor).
Custom Zar2 antibody preparation
Anti-C-Zar2 antibodies were raised in rabbit against peptides
encoding C-terminus (amino acids 267–286) of Zar2 and anti-N-
Zar2 antibodies were raised against N-terminus (amino acids
29–44) and puriﬁed by peptide column (Proteintech). To test
antibody speciﬁcity, 1.5 mg/ml of the immunizing peptide was
incubated 1 h, 25 1C with the primary antibody before adding to
the transfer membrane.
RNA immunoprecipitation and analysis
Pools of 50 oocytes were lysed in 500 ml homogenization
buffer (150 mM NaCl, 50 mM Tris pH 7.5, 0.5% NP40, 2% BSA)
supplemented with 10 mM ribonucleoside vanadyl complex
(NEB), HALT protease inhibitors, RNaseOUT (Invitrogen) and
1 mM DTT. Lysates were clariﬁed by centrifugation 25 min,
14,000 g, 4 1C. 4 mg of antibody was added and incubated for
6 h, 4 1C. 30 ml of a 1:1 slurry of protein A/G PLUS-agarose (Santa
Cruz Biotechnology) was added and samples were rotated for
30 min. Agarose beads were washed twice with homogenization
buffer and twice with NP40 lysis buffer. 5 oocyte equivalent of
beads was used to analyze immunoprecipitation efﬁciency by
western blot. RNA was extracted from the beads using RNA STAT-
60 (Tel-Test) according to manufacturer0s directions.
The amount of immunoprecipitated RNA was determined by
semi-quantitative PCR. cDNA was synthesized from 40 oocyte
equivalents of RNA using iScript (Bio-Rad). 1 ml of cDNA was
ampliﬁed using Platinum Taq (Invitrogen). Annealing was per-
formed at 60 1C. The following gene-speciﬁc primers and cycles
were used: Mos (f) 50-GAG AAT CAC AGT TCC ACA GCA ACC, Mos
(r) 50-AGA CAG TTC CCC CAA CAG AAG C, 30 cycles; Wee1a (f)
50-TGC CGG AAG CAG ACA GAG TTG G, Wee1a (r) 50-TTA GCG GCT
TTC AAC TCC CTC TCA, 25 cycles; Protein Phosphatase Inhibitor 2
(PPI2) (f) 50-CGT GTC ATT AGC AAG CCA GAG AC, PPI2 (r) 50-GCA
ATC AAG TGT CTG GCG AGT C, 40 cycles. The cycle number was
determined by running 1/100 and 1/1000 oocyte equivalent of
cDNA from total RNA and making sure there was a difference in
the amount of PCR product between these two amounts of cDNA.
Also, these standards were used to normalize the exposure of the
gels so all the positive controls look the same and the immuno-
precipitated mRNAs can be directly compared.
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Total RNA was extracted from pools of 20 oocytes using
Tri Reagents Solution (Ambion) according to manufacturer0s
directions. A LiCl precipitation step was included for further
puriﬁcation. cDNA was synthesized from 2 mg of total RNA using
Superscript III (Invitrogen) and oligo dT(12–18) according to manu-
facturer0s directions. PCR was performed in duplicate (only one
set of bands is shown) using One TaqTM Hot Start (New England
BioLabs) according to manufacturer0s directions. Forward primer
was ﬂuc 50-TCT TCC CGA CGA TGA CGC, reverse primer was b-
globin 50-AGA CTC CAT TCG GGT GTT CTT GAG G. Annealing was
carried out at 56 1C and the reaction proceeded for 26 cycles.
Quantitative range was determined by using dilutions of the
control cDNA.Results
Isolation of a protein that interacts with the TCS
A previous study screened an unfertilized Xenopus laevis egg
library to identify proteins that bound to the MBE in the 30 UTR of
the Mos mRNA (Charlesworth et al., 2006). One of the proteins
that was isolated was Musashi and we showed that Musashi
bound to the MBE in the Mos 30 UTR. Another protein, designated
A8, was isolated in that screen, and we characterize A8 in this
study. The screen was performed with the Mos M1 48 Mos UTR
where the last 48 nucleotides of the Mos UTR with a mutationMBE
X
X
MS2 Mos WT 48
MS2 Mos M1 48
MS2 MosΔMBE
MS2 MosΔTCS 
MS2 βg/TCS
MS2 βg
TCShex
MS2 Wee WT
MS2 WeeΔTCS 
MS2 IRE
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A
Fig. 1. Characterization of a TCS binding protein by yeast three hybrid analysis. (
polyadenylation hexanucleotide; red oval, TCS; X, disrupted CPE; dotted line, deleted se
assay for lacZ expression. Blue color indicates RNA–protein interaction. Yeast were tran
and three independent colonies streaked for each analysis. A8 interacts with sequences
Wee1 30 UTR, and a TCS inserted into the b-globin 30 UTR. (C) Yeast three hybrid liquid
and protein hybrids. Chart shows b-galactosidase activity. The IRE/Iron Response Pro
b-galactosidase activity was observed when the TCS was present in the b-globin 30 UT(M1) in the CPE (UUUAAU to UUUggU) were used to prevent
recovery of CPEB. As A8 was recovered on Mos M1 48 this
demonstrated that A8 did not bind to the CPE. The yeast three
hybrid assay was further used to determine where A8 interacted
with the Mos UTR. To show that A8 interaction was not an artifact
of binding to the mutant CPE, the CPE was restored to make Mos
WT 48. A8 still interacted with Mos WT 48 showing that the
interaction was not an artifact of the mutant CPE. The interaction
did not appear as strong for unknown reasons. Next we tested if
A8 interacted with the MBE in the Mos 30 UTR. The MBE was
deleted from the Mos 30 UTR in the RNA hybrid to make Mos
DMBE as shown in Fig. 1A. Removal of the MBE (Mos DMBE) did
not prevent interaction with A8 (Fig. 1B), indicating that A8 does
not interact with the MBE and likely interacts with a different
element within the 30 UTR of Mos mRNA. The only place left for
this element to be located was 30 of the polyadenylation hexanu-
cleotide. Accordingly, when these seven nucleotides at the very 30
end of the UTR were deleted to make Mos DTCS, interaction with
A8 was abrogated. Sequence analysis revealed that these seven
nucleotides were remarkably similar to the TCSs in the Wee1 30
UTR. This suggested that Mos has a TCS (MacNicol and MacNicol,
2010) and that A8 was a TCS-interacting protein. The Wee1 30 UTR
has three maturation-type CPEs (Charlesworth et al., 2000) and
two TCSs between the ﬁrst two CPEs (Wang et al., 2008). To test if
A8 interacted with other TCSs, the Wee1 30 UTR was used in
the yeast three hybrid assay, either with the TCSs intact (wild
type, Wee WT) or with the TCSs deleted (Wee DTCS) (Fig. 1A).
A8 interacted with Wee WT, but not when the TCSs were deleted
(Wee DTCS), indicating that the TCS is necessary for interactionMS2-IRE
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A) Cartoon of the RNA hybrids used: white oval, MBE; square, CPE; hexagon,
quences; bold line, Iron Response Element (IRE). (B) Yeast three hybrid colony lift
sformed with pACT2-A8 and pIIIA plasmids containing the indicated RNA hybrids
30 of the polyadenylation hexanucleotide in the Mos 30 UTR, the TCS region in the
culture assay for lacZ expression. Yeast were transformed with the indicated RNA
tein (IRP) interaction serves as a positive control (SenGupta et al., 1996). More
R.
A. Charlesworth et al. / Developmental Biology 369 (2012) 177–190182with A8 (Fig. 1B). It should be noted that the Wee DTCS construct
still contains two intact CPEs, further showing that A8 does not
interact with CPE sequences. To test if the TCSs are sufﬁcient for
interaction with A8, we inserted the Mos TCS into b-globin 30 UTR
(bg/TCS). A8 did not interact with wild type b-globin 30 UTR (bg),
but did interact with bg/TCS, as assessed by both colony lift assay
(Fig. 1B) and liquid culture assay (Fig. 1C). These data demon-
strate that a TCS is necessary and sufﬁcient for interaction
with A8.Identiﬁcation of A8
BLASTs (NCBI) analysis showed that the amino acid sequence
of A8 was similar to the entire C-terminal half (i.e. amino acids
159–307) of mouse Zygote arrest1 (Zar1) (Wu et al., 2003a).
To ensure that the most complete and accurate 50 end of A8 was
identiﬁed for analysis and cloned for mechanistic studies, 50 RACEZar1
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Fig. 2. A8 is the C-terminal of Zar2. (A) Alignment of Xenopus laevis Zar1 and Zar2 am
below the sequences designates the start of A8. Shaded areas indicate identical amino a
below the sequence. Cysteine pairs conserved in both Zar1 and Zar2 proteins are high
interest in bold text. Genbank accession numbers are: Zar1, AAP37038; Zar2a, BAH367
between C215 and C242, and the putative loop 2 is between C259 and C287. (B) Propos
regions of high sequence homology between Zar1 and Zar2 while red lines indicate con
A8, depicted as a blue line.from two individual frogs was performed. The full-length
sequence of A8 was 1128 nt, predicting a protein of 307 amino
acids. Upon comparison, the full-length sequence of A8 was more
similar to zar2 (Nakajima et al., 2009), which was identiﬁed
during the timeframe of this study, than to Xenopus laevis Zar1
(Genbank ID: AY283176) (Wu et al., 2003b) (Fig. 2A). We propose
we have cloned the paralog of zar2 arising from the pseudote-
traploid nature of Xenopus laevis. Further, we suggest that zar2
(Genbank ID: AB190316) (Nakajima et al., 2009) be designated as
zar2a and our sequence from this point forward be designated as
zar2b (Genbank ID: JQ776638). According to this proposed
nomenclature, all experiments in this study were performed with
zar2b. In addition to the observed C-terminal conservation
between Zar1 and Zar2 proteins, an area of homology in the
N-terminal was also observed. In the subsequent experiments,
we show that the C-terminal half of Zar2 binds RNA and the
N-terminal half regulates mRNA translation, as summarized in
Fig. 2B.30 40 50
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ino acid sequences was performed using MacVector 11.1.2. A blue box and arrow
cid residues. Residues targeted by antibodies are highlighted in yellow and labeled
lighted in red. Cysteines targeted for mutation are indicated below the residue of
46; and zar2b (Zar2b), JQ776638. For purposes of discussion, the putative loop 1 is
ed schematic of Zar protein regions and functions. Shaded areas (in grey) represent
served cysteine pairs of interest. The box and arrow designate the boundary of the
A. Charlesworth et al. / Developmental Biology 369 (2012) 177–190 183Expression of Zar2 during oogenesis and meiotic maturation
The data in Fig. 1 suggested that Zar2 might bind to maternal
mRNAs that are regulated during oocyte maturation. To further
this line of study, it was essential to determine if Zar2 protein is
present in Xenopus oocytes. To do this we raised antibodies to
peptides in the C-terminal and N-terminal domains. An antibody
speciﬁc to a peptide in the C-terminal domain that had the most
mismatches between Zar2 and Zar1 (amino acids 267–286)
(Fig. 2A) was developed. To test that the antibody recognized
Zar2, we expressed GST-Zar2 in immature oocytes. The C-term-
inal Zar2 antibody recognized a band at the same size as the GST
antibody (Fig. 3A). To show speciﬁcity we blocked the antigen
binding sites on the C-terminal Zar2 antibody by incubating with
the immunizing peptide before western blot. This treatment
prevented the C-terminal Zar2 antibody from recognizing GST-
Zar2, demonstrating that the antibody was speciﬁc. Recognition
of Zar2 and not Zar1 by the C-terminal antibody was veriﬁed by
western blot of recombinant proteins (Fig. 3D). The C-terminal15
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Fig. 3. Zar2 protein expression during oogenesis and oocyte maturation. (A–D). Charact
uninjected (–) or GST-Zar2-expressing (þ) immature oocytes were analyzed by the pur
indicated. The immunizing peptide 267–286 (A), or 29–44 (B), was used to block speciﬁ
immature (I) or progesterone-stimulated mature (P) oocytes were analyzed with both
Lysates from immature oocytes expressing GST-C-Zar2 or GST-C-Zar1 were analyzed by
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blots are shown. Similar results were obtained in oocytes from 4–5 different frogs. (E) P
VI or a single in vitro matured oocyte (egg) (E) was loaded. (F) 3.75 mg of total protein
stimulation and protein equivalent to 0.5 oocyte was loaded.antibody is used for western blot. We also raised an antibody for
immunoprecipitation against a peptide in the N-terminal of Zar2
that was predicted to be on the surface of the protein, amino acids
29–44 (Fig. 2A). These amino acids are not conserved at all
between Zar2 and Zar1. We analyzed the N-terminal antibody
in a similar fashion to the C-terminal antibody (Fig. 3B). The
N-terminal antibody recognized GST-Zar2 and this recognition
was blocked by the immunizing peptide. We use the N-terminal
antibody mainly for immunoprecipitation (Fig. 6), however, it is
also useful for western blot. To test if the antibodies could detect
endogenous Zar2 we western blotted lysates from immature and
progesterone-stimulated mature oocytes (Fig. 3C). Both Zar2
antibodies recognized a band that migrated about 39 kDa
and for both antibodies this band was more intense in imma-
ture oocytes compared to mature oocytes. We conclude that
endogenous Zar2, which has a predicted molecular weight of
35 kDa, migrates at 39 kDa on a polyacrylamide gel, similar to
mouse Zar1 (Wu et al., 2003a). We have expressed different
truncations of Zar2 with different tags in several eukaryotic cellTubulin
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A. Charlesworth et al. / Developmental Biology 369 (2012) 177–190184types and Zar2 consistently migrated slightly larger than pre-
dicted (data not shown), which suggests post-translational mod-
iﬁcation. The C-terminal antibody recognized an additional band
that migrated at 32 kDa (Fig. 3), however, the 32 kDa band was
not detected by the N-terminal antibody (Fig. 3C), suggesting that
amino acids 29–44 were not present and that the 32 kDa band is
therefore not an unmodiﬁed version of Zar2. A similar smaller
band was also seen with antibodies to mouse Zar1, and it was
proposed that this might be a degradation product (Wu et al.,
2003a). Although it has been shown that the 50 end of the Zar1
mRNA undergoes alternative splicing in several species
(Uzbekova et al., 2006), isolation of the 50 end of zar2 did not
reveal any evidence of alternative 50 ends in our hands. At this
time, we do not know if the smaller band recognized by the
C-terminal Zar2 antibody is a degradation product, a product of
alternative splicing or a cross-reacting protein that is not Zar2.
The C-terminal antibody also recognizes a band at 20 kDa. As this
band follows the same pattern as Tubulin expression (Fig. 3E–G),
we think it is an unrelated cross-reacting band.
Using the C-terminal antibody, Zar2 protein levels during
oogenesis were characterized. The total amount of Zar2 per
oocyte increased during stages I–IV of oogenesis (Dumont,
1972), as the oocytes grow in size. Zar2 reached maximum levels
at stage IV, even though the oocyte continues to grow in size from
stage IV to stage VI, as seen by the increase in Tubulin (Fig. 3E).
However, it was stage I oocytes that had the greatest concentra-
tion of Zar2 relative to Tubulin (Fig. 3F). Interestingly, the 32 kDa
band showed a similar proﬁle. These data suggest that Zar2 might
play a role in early oogenesis.
Next, we characterized Zar2 levels during meiotic maturation.
Levels of Zar2 gradually declined during oocyte maturation
(Fig. 3G). In mature oocytes, there was a 60–80% (n¼5) decrease
in the amount of endogenous Zar2 compared to immature
oocytes. Interestingly, the 32 kDa band showed a similar proﬁle.
Thus Zar2 protein is present in immature oocytes, consistent with
a role in maternal mRNA regulation.
Zar2 binds speciﬁcally to the TCS
As A8 (the C-terminal domain of Zar2) interacted with TCSs in
the Wee1 and Mos 30 UTRs (Fig. 1), we examined whether Zar2
directly binds to the TCS by the use of electrophoretic mobility
shift assays (EMSA). In these experiments 50 nt of the Wee1
30 UTR, very close to the poly(A) tail, were used as the labeled
probe (Fig. 4A). The cis elements are indicated. There are three
CPEs and two TCSs. The TCSs overlap with the CPEs. The nucleo-
tides of the TCS mutation (UU to gg) that disrupt polyadenylation
and translation control (Wang et al., 2008) are marked in red.
The C-terminal of Zar2 was FLAG-tagged (FLAG-C-Zar2) and
expressed in Sf9 cells. The binding of FLAG-C-Zar2 to the Wee1
30 UTR was determined. Fig. 4B shows that a speciﬁc complex
forms when FLAG-C-Zar2 is puriﬁed from baculovirus infected Sf9
cells but not with proteins mock puriﬁed from uninfected cells.
Also there was no speciﬁc complex formed when the FLAG elution
buffer was used in the EMSA. This shows that the speciﬁc
complex was not formed from endogenous insect proteins or
from FLAG peptides. The speciﬁc complex could be supershifted
by antibodies to FLAG and Zar2, but not by antibodies to Tubulin,
showing that the complex contained FLAG-C-Zar2 (Fig. 4B).
To show that Zar2 was targeting the TCS in the Wee1 30 UTR,
we used competition assays with unlabeled RNA specifying the
same 50 nt as the labeled Wee1 probe. The labeled probe could be
competed with a 50-fold excess of unlabeled Wee1 UTR, but it
could not be competed when the TCSs in the unlabeled RNA were
disrupted (red UU mutated to gg) (Fig. 4C). It should be noted that
mutation of TCS1 also disrupts CPE1, however there are two otherCPEs present in the unlabeled probe and neither of them com-
petes with the labeled probe for Zar2 binding. These results
indirectly show that Zar2 binds to the TCS. To directly show that
Zar2 binds to the TCS, we used labeled probes where the TCSs had
the same mutations as in the competition study. For these
experiments, puriﬁed bacterially expressed Zar2 proteins were
used. First, we veriﬁed that GST-tagged Zar2 expressed in E. coli
binds to the Wee1 30 UTR. Fig. 4D shows that GST-C-Zar2 bound
to the Wee1 30 UTR, but GST alone or the N-terminal of Zar2
(GST-N-Zar2) did not bind, even though equivalent amounts of
protein were used (Fig. 4D lower panel). Next, we asked if GST-C-
Zar2 could bind to mutant Wee1 UTRs. When either TCS1 or TCS2
was disrupted, the binding of Zar2 was unchanged (Fig. 4E).
However, when both TCSs were disrupted, binding of Zar2 to
the Wee1 30 UTR was markedly reduced. The number of CPEs was
the same in the TCS1 mutant versus the TCS1&2 mutant showing
that the change in binding was not due to Zar2 binding to the
CPEs. Increasing amounts of Zar2 protein showed a dose response
with respect to the amount of complex formed, verifying the
speciﬁcity of this reaction. Because only one speciﬁc complex is
seen, these data show that Zar2 can bind to either TCS, but two
Zar2s do not bind to both TCSs at the same time.
Zar2 contains a zinc ﬁnger
The conserved C-terminus of Zar1 has been speculated to
contain an atypical PHD domain, a fungal C6 domain, or a FYVE
domain based on conserved cysteine residues (Sangiorgio et al.,
2008; Uzbekova et al., 2006; Wu et al., 2003a). All of these
domains are zinc ﬁngers, but they are found in proteins with
different functions, such as histone modiﬁcation, phospholipid
binding and DNA binding (Matthews and Sunde, 2002; Todd and
Andrianopoulos, 1997). Also, it is not known which cysteines in
Zar1 form the putative zinc ﬁnger(s). To test whether the
C-terminal of Zar2 contained a zinc ﬁnger, we puriﬁed the protein
from bacteria in the presence of EDTA to remove pre-incorporated
Zn2þ and then performed the EMSA either with or without adding
back Zn2þ to the binding buffer. EDTA treatment also removed
Mg2þ that was essential for Zar2 RNA binding, but activity was
recovered when Mg2þ was added back to the binding buffer (data
not shown). In decreased Zn2þ conditions (but normal Mg2þ
conditions), the binding of Zar2 to the Wee1 30 UTR was
dramatically reduced (Fig. 5A), demonstrating that Zar2 binds to
RNA using a zinc ﬁnger. To substantiate this result, we mutated
one cysteine in each conserved pair of cysteines illustrated in
Fig. 2. The ability of the mutant proteins to bind the Wee1 30 UTR
was assessed by EMSA. Mutating any of these four pairs of
cysteines abolished binding of Zar2 to the Wee1 30 UTR
(Fig. 5B), even though equivalent amounts of protein were used
(Fig. 5B, lower panel). These results demonstrate that Zar2
binding to RNA is dependent on the structural integrity of a zinc
ﬁnger.
Endogenous maternal mRNAs are targets for Zar2 in Xenopus oocytes
Our previous results assessed the in vitro interaction of
recombinant Zar2 with synthetic RNA. To test whether these
interactions actually occurred in the immature Xenopus oocyte,
endogenous Zar2 was immunoprecipitated from immature
oocytes (Fig. 6A) using the N-terminal Zar2 antibody (Figs. 2
and 3). RNA was extracted from the immunoprecipitate, and the
presence of the endogenous Wee1 or Mos mRNA was assessed by
semi-quantitative RT-PCR. The PCR conditions were optimized to
be able to distinguish a 10-fold difference in total RNA (total
1/100 vs total 1/1000). Endogenous Wee1 mRNA co-precipitated
with endogenous Zar2 indicating that Zar2 interacts with Wee1
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Fig. 4. Zar2 binds to TCSs in Wee1 30UTR in vitro. (A) Diagram showing the Wee1 UTR probe used in these studies: box, CPE; red oval, TCS; hexagon, polyadenylation
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FLAG-C-Zar2 proteins. Antibodies against bTubulin, FLAG or C-terminal Zar2 were added where indicated. (C) EMSA showing that speciﬁc complex formation can be
competed with unlabelled RNA containing TCSs. The Wee1 RNA probe was incubated FLAG-C-Zar2 protein, and the unlabeled RNAs were used to compete for labeled probe
binding. A 50-fold molar excess of wild type (WT) or TCS-disrupted (mt) Wee1 30 UTR was used. (D) Upper panel, EMSA showing bacterially expressed GST-C-Zar2, but not
GST-N-Zar2, binds to Wee1 30UTR. The Wee1 probe was incubated with GST alone, GST-N-Zar2 or GST-C-Zar2 proteins. Lower panel, western blot with GST antibodies
showing that equivalent amounts of proteins were expressed. (E) EMSA showing that Zar2 directly binds to the TCSs in the Wee1 UTR. Wee1 probes with mutations in TCS
1 (TCS mt1), TCS 2 (TCS mt2) or both TCSs (TCS mt1&2) were used. These mutant probes were incubated with decreasing amounts of GST-C-Zar2 from 15 mg to 24 ng in a
5-fold dilution series. Below each gel is a diagram of the probe that was used showing which TCSs or CPEs were present. Mutating either TCS alone did not affect binding,
but mutating both TCSs markedly reduced binding of GST-C-Zar2.
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Fig. 6. Endogenous Zar2 interacts with endogenous mRNAs in immature oocytes.
(A) Western blot showing immunoprecipitation of Zar2. Immature oocytes were
lysed and Zar2 immunoprecipitated with the Zar2 N-terminal antibody (a-Zar2)
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Zar2 immunoprecipitates and were not detected in the mock immunoprecipita-
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cipitated than is found in 1/100 of an oocyte (we estimate 1/30).
As we originally found Zar2 because it interacted with the Mos 30
UTR, we tested if endogenous Mos mRNA co-precipitated with
Zar2. Fig. 6B shows that Mos mRNA also co-precipitates with
Zar2. The Mos mRNA that was immunoprecipitated was more
than 1/1000 but less than 1/100 of an oocyte (we estimate 1/200).
In contrast, the protein phosphatase inhibitor 2 mRNA, a negative
control (Charlesworth et al., 2006), showed much lower afﬁnity
and the amount of PPI2 mRNA that was immunoprecipitated
was close to that found in 1/1000 of an oocyte. These data show
that endogenous Zar2 preferentially co-immunoprecipitates with
Wee1 and Mos mRNAs.
Zar2 represses translation in immature oocytes and repression is
relieved during maturation
The TCS confers translational repression in immature oocytes
and translational activation in meiotically maturing oocytes
(Wang et al., 2008). If Zar2 is a trans-acting factor for the TCS,
then it too should repress translation in immature oocytes and/or
stimulate translation in maturing oocytes. To test this, we used
the tethered assay, where viral MS2 coat protein fusions bind to
MS2 stem–loops in the reporter RNA, thus tethering the MS2 coat
proteins to the RNA ((Gray et al., 2000), reviewed recently in
Minshall et al., 2010). This method separates effects on transla-
tion regulation from changes in RNA binding. The ﬁreﬂy luciferase
reporter construct contained MS2 stem–loops (ﬂuc-2x-SL),
whereas Renilla luciferase did not contain MS2 stem–loops and
was used as a loading control (Fig. 7A). Since the C-terminal
domain of Zar2 is the RNA binding domain (Figs. 1 and 4),we hypothesized that the N-terminal contains the translational
activation domain. Therefore, we replaced the C-terminal domain
of Zar2 with MS2 coat protein (Fig. 7A). MS2-Xp54 was used as a
positive control for translational repression (Minshall et al., 2001).
Oocytes were injected with mRNA encoding the indicated MS2
fusion protein and incubated overnight to allow expression.
Oocytes were then injected with the luciferase translation repor-
ter constructs. Progesterone was added to half the oocytes and all
oocytes were incubated until the progesterone-stimulated
oocytes were at meiosis II. Oocytes were lysed and the amount
of luciferase protein accumulated was measured. Fireﬂy luciferase
is reported relative to Renilla luciferase (Fig. 7B). Oocytes not
expressing a fusion protein (–) showed no signiﬁcant difference in
translation of ﬁreﬂy luciferase mRNA from oocytes expressing
MS2, verifying that the binding of MS2 to the reporter mRNA does
not stimulate or repress translation, as expected (Gray et al.,
2000). Also, MS2-Xp54 repressed translation of ﬁreﬂy luciferase
by about 60% compared to MS2 alone (in agreement with
Minshall et al., 2001). MS2 and MS2-Xp54 were expressed at
equivalent levels (Fig. 7C). When N-Zar2-MS2 was tethered to the
luciferase reporter, it repressed translation in immature oocytes
by up to 3377.5%. This decrease in translation was not due to
destabilization of the ﬁreﬂy RNA reporter as assessed by semi-
quantitative PCR (Fig. 7F). Increasing amounts of injected RNA
resulted in increasing amounts of N-Zar2-MS2 fusion protein that
accumulated (Fig. 7C) and increasing amounts of repression,
showing that the observed repression is due speciﬁcally to the
presence of the N-Zar2-MS2 fusion protein. At the highest dose
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A. Charlesworth et al. / Developmental Biology 369 (2012) 177–190 187
A. Charlesworth et al. / Developmental Biology 369 (2012) 177–190188tested, N-Zar2-MS2 protein expression was similar to MS2 and
MS2-Xp54 (Fig. 7C). Data were analyzed using one-way ANOVA
and differences in means with a p-valueo0.01 (nn) were con-
sidered signiﬁcant. When 20 ng or 50 ng of N-zar2-MS2 RNA was
injected, signiﬁcant repression was observed. Additionally,
Mann–Whitney U tests were performed to assess differences in
median values with similar conclusions. Repression of translation
was speciﬁc to N-Zar2-MS2 being tethered to the RNA, as no
repression was seen when the stem–loops were omitted from the
ﬁreﬂy luciferase reporter (ﬂuc) (Fig. 7D), even though proteins
were expressed at similar levels (Fig. 7E).
Next, we determined whether the translational control exerted
by Zar2 changed during meiotic maturation of Xenopus oocytes.
Accumulation of luciferase in MS2-, or MS2-Xp54-expressing
oocytes, or oocytes not expressing fusion proteins (–), did not
change during maturation (Fig. 7B). However, N-Zar2-MS2-
mediated repression was relieved during oocyte maturation
(Fig. 7B). This change was observed at all levels of protein
expression and was determined to be signiﬁcantly different
(p-value o0.01)(nn) using one-way ANOVA and Mann–Whitney
U test. Because N-Zar2-MS2 binds to luciferase through MS2 coat
protein: stem–loop interactions, RNA binding does not change
during maturation. Rather, relief of repression could be due to loss
of N-Zar2-MS2, as protein levels were markedly lower in proges-
terone treated samples (Fig. 7C). There was a 70–80% (n¼5)
reduction in N-Zar2-MS2 in progesterone-treated oocytes, which
is comparable to the reduction in endogenous Zar2 during oocyte
maturation (Fig. 3G).
Taken together, these results show that Zar2 repressed trans-
lation in immature oocytes and that repression was relieved in
maturing oocytes.Discussion
The closely related Zar1 and Zar2 proteins are implicated in
early zygotic progression, but their mechanism of action is
unknown. Histone modiﬁcation, transcriptional regulation and
RNA metabolism have all been proposed. Here we showed that
Xenopus Zar2 binds maternal mRNAs and regulates translation.
Zar2 is a trans-acting factor for the TCS
The maternal Wee1 mRNA has been shown to contain two TCS
cis-elements that repress translation in immature oocytes and
activate translation in maturing oocytes (Wang et al., 2008). This
study provides evidence that Zar2 is a trans-acting factor for the
TCS. Several criteria are necessary to support this conclusion: Zar2
should bind to the TCS, repress translation in immature oocytes,
and activate translation during meiosis. In support of these
criteria we show the following pieces of evidence. (1) Zar2
associates with Wee1 and Mos mRNAs in vivo. In yeast cells, a
Zar2 fusion protein interacts with Mos and Wee1 30 UTRs (Fig. 1).
The TCS was necessary and sufﬁcient for Zar2 interaction with the
RNA hybrid. Moreover, endogenous Wee1 and Mos mRNAs can be
co-immunoprecipitated with endogenous Zar2 from immature
oocytes (Fig. 6). (2) Zar2 binds directly to the TCS in vitro. Zar2
forms a speciﬁc complex with Wee1 RNA and labeled probe
binding in the speciﬁc complex was competed by unlabeled
RNA that contained a TCS (Fig. 4). Furthermore, when the TCSs
were disrupted, the speciﬁc complex showed markedly reduced
binding (Fig. 4E). (3) Zar2 represses translation in immature
oocytes. This is an important criterion, as this is the translational
activity that the TCS confers to RNA reporters (Charlesworth et al.,
2000; Wang et al., 2008). In this study, we show that Zar2
repressed translation of a luciferase reporter in immature oocytes(Fig. 7). This translational repression is about 33% at the max-
imum Zar2 dose that was injected. This is comparable to the TCS
in the Wee1 30 UTR that contributes about 33% repression in
immature oocytes (Wang et al., 2008). Thus, we propose that Zar2
is a trans-acting factor for the TCS.
The TCS also confers translational activation in maturing
oocytes (Wang et al., 2008). The activation of mRNA translation
by Zar2 during meiosis has not been established in this study.
However, Zar2-mediated repression was relieved during meiosis.
One reason for the relief of repression and not activation may be
that N-Zar2-MS2 is degraded during meiosis so N-Zar2-MS2
could not repress, nor could it activate translation. Interestingly,
the endogenous Zar2 protein is partially degraded during
meiosis (Fig. 3), so degradation might be part of the mechanism
of action of Zar2. Degradation of Zar2 might appear to be contra-
dictory for a role in embryogenesis. However, it is known that
approximately 80% of CPEB is degraded during meiosis (Mendez
et al., 2002), and the remaining CPEB plays an important role in
translating cyclin B1 mRNA during the ﬁrst mitotic cell cycles
(Groisman et al., 2000). Alternatively, the regulation of
TCS-containing mRNAs may be controlled by more than one
trans-acting factor. For example, Zar2 might repress translation
of TCS-containing mRNAs during oogenesis. After degradation
of Zar2 during meiosis, another protein may load onto the TCS-
containing mRNA to activate translation. Precedent for protein
switching in the regulation of translational control comes from
analysis of CPEB4 protein, which replaces CPEB1 during Xenopus
meiotic maturation (Igea and Mendez, 2010). We are initiating
studies to assess TCS-directed translational activation during
maturation.
Zar2 and transcriptional regulation
Mouse Zar2 (Zar1l) co-localizes with P-body components,
RAP55 (aka Lsm14a) and LIN28, to cytoplasmic foci in 2-cell
embryos (Hu et al., 2010). This suggests that Zar2 is found in
P-bodies, which are sites of mRNA translational repression and
degradation (Balzer and Moss, 2007; Parker and Sheth, 2007;
Yang et al., 2006). That Zar2 may be a component of P-bodies is
consistent with our results demonstrating that Xenopus Zar2
binds mRNA and represses translation. The original proposal that
Zar1 regulated transcription was based on the observation that in
embryos from Zar1-null mice, the zygotic genome was not
activated (Wu et al., 2003a). More speciﬁcally, the embryos did
not activate transcription of Transcription Requiring Complex
(TRC), a marker of embryonic genomic activation (Wu et al.,
2003a). Consistent with this is the observation that a dominant
negative Zar2/Zar1l also disrupted general transcription (Hu et al.,
2010). One explanation for these observations could be that
zygotic transcription is activated by the protein product of a
Zar2 target mRNA. However, it should be noted that although we
have shown that Xenopus Zar2 binds to RNA, this does not
necessarily mean that the Zar family of proteins are not transcrip-
tional regulators as well as translational regulators. ChIP analysis
of Zar2 in human breast cancer cells shows that Zar2 interacts
with the BRCA2/Zar2 bidirectional promoter (Misra et al., 2010).
Furthermore, dual function zinc ﬁngers are not without
precedent. Wilms0 Tumor 1 protein and TFIIIA contain zinc ﬁngers
that bind both RNA and DNA, and regulate gene expression both
transcriptionally and post-transcriptionally (Hall, 2005; Morrison
et al., 2008; Burdach et al., 2012).
Zar2 contains a new type of zinc ﬁnger
Central to the predicted function of the Zar proteins are the
conserved cysteines in the C-terminal domain. There are 12
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that different cysteines may form different types of zinc ﬁngers,
however, these cysteines are not recognized by protein motif-
predicting software. Zar proteins contain pairs of cysteines (C–X2–
C) similar to zinc knuckles that are found in zinc ﬁngers with
interleaved pairs of cysteines/histidines, in a cross-brace topol-
ogy, such as FYVE (C4–C4) (phospholipid binding), PHD (C4–HC3)
(chromatin modiﬁcation) and RING (C4–HC3) (ubiquitination)
domains (Matthews and Sunde, 2002). However, motifs such as
PHD domains and FYVE domains require speciﬁc amino acids
relative to the cysteines, which Zar proteins do not have. Also,
Zar proteins tend to have more amino acids between the cysteine
pairs in the loops (22–33 aa) than PHD or FYVE domains
(10–18 aa) (Bienz, 2006; Gillooly et al., 2001) (see Fig. 2 legend
for putative loop positioning). Furthermore, loop 1 is separated
from loop 2 by four amino acids in FYVE and PHD domains and
thirteen in Zar proteins. Ring ﬁngers do tend to have more amino
acids in the loops, between the pairs of cysteines/histidines
(30–40), similar to Zar proteins but the two loops in RING ﬁngers
are spaced only 2–3 amino acids apart (Budhidarmo et al., 2012).
Zar proteins also have conserved cysteines and histidines that are
not in closely spaced pairs, similar to other zinc ﬁngers such as
binuclear clusters and classical zinc ﬁngers (DNA binding), CCCH
proteins (mRNA stability, AU-rich element (ARE) binding protein),
RANBP2 proteins (splicing) and the zinc ﬁnger of CPEB (maternal
mRNA regulation) (Brown, 2005; Burdach et al., 2012; Hake et al.,
1998; Hall, 2005; Kutateladze, 2006; Loughlin et al., 2009).
However, the spacing of the cysteines and histidines that are
not in CxxC pairs in Zar proteins do not match the spacing of any
of these zinc ﬁngers. Thus, the cysteines in Zar2 share similarities
with all these types of zinc ﬁngers, but lack various characteristics
that would ﬁrmly place Zar2 in any one of these categories. We
show here for the ﬁrst time that a Zar protein requires Zn2þ for a
biological function. We showed that Zar2 binding to the Wee1
RNA probe was markedly reduced in the absence of Zn2þ
(Fig. 5A). Moreover, we identiﬁed four pairs of cysteines that are
important for RNA binding (Fig. 5B), supporting predictions that
Zar proteins contain zinc ﬁngers. We further propose that Zar
proteins have a new type of functional zinc ﬁnger motif.
Physiological role of Zar2 and target mRNAs
Although Zar2 regulates translation during oocyte maturation,
we have been unsuccessful in showing a role for Zar2 in oocyte
maturation. However, it should be noted that Zar2 might not
regulate meiosis because it is the downstream protein products of
the target mRNAs of Zar2 that will determine the physiological
role of Zar2. Although the Wee1 mRNA is translated during oocyte
maturation (Charlesworth et al., 2000), the resulting Wee1
protein is implicated in the ﬁrst embryonic mitotic cell cycle,
and not meiosis (Murakami et al., 1999; Murakami and Vande
Woude, 1998). Indeed, studies in mice with disrupted Zar pro-
teins have shown embryonic defects around the 1- and 2-cell
stage rather than meiotic defects (Hu et al., 2010; Wu et al.,
2003a). Wee1 protein is also important at gastrulation (Murakami
et al., 2004), which occurs later during Xenopus development.
Moreover, in Xenopus embryos, it has been shown that Zar2 plays
a role in production of secreted factors involved in epidermaliza-
tion (Nakajima et al., 2009), which also occurs later in develop-
ment. We propose that Zar2 represses TCS-containing maternal
mRNAs until they are required for embryogenesis. Also, we expect
that Zar2 regulates translation of maternal mRNAs other than
Mos and Wee1.
Zar2 may also play a role repressing maternal mRNAs during
oogenesis. The amount of Zar2 increases during oogenesis as the
oocytes grow in size, reaching a maximum at stage IV (Fig. 3).However, the concentration of Zar2 relative to Tubulin is remark-
ably high in stage I oocytes compared to stage VI oocytes.
Maternal mRNAs are repressed by multiple mechanisms through-
out development (Colegrove-Otero et al., 2005), and during
oogenesis it is known that the mechanism of CPEB-mediated
repression changes as different partner proteins are expressed at
different stages (Radford et al., 2008). Therefore, it is conceivable
that Zar2 could provide yet another mechanism of translational
repression early in oogenesis. Identiﬁcation of additional Zar2
target mRNAs and their regulation during oogenesis and embry-
ogenesis will help elucidate the physiological role of Zar2. 147
maternal Xenopus 30UTRs were identiﬁed as being candidates for
containing TCSs (Wang et al., 2008). Testing whether those
mRNAs can interact with Zar2 will advance this goal.
Zygote arrest proteins and pathological conditions
In this report, we have shown that Xenopus Zar2 binds to the
TCS in maternal mRNAs and represses translation in immature
oocytes. Because of the areas of conservation in the C-terminal,
we expect Zar1 to also bind RNA. There is also homology between
Zar1 and Zar2 in the N-terminal domain and so we expect Zar1 to
also regulate translation. Expression of Zar1 and Zar2 is normally
conﬁned to oocytes and early embryos. However, recently, it has
been reported that Zar transcripts and Zar proteins are expressed
in a variety of cancers. Zar2 is expressed in human breast cancer
cells where it binds to the BRCA2 gene promoter and represses
expression of BRCA2 during G0/G1 (Misra et al., 2010). In addition,
the Zar1 gene is aberrantly methylated and over-expressed in
malignant melanoma cells (Shinojima et al., 2010). The Zar1 gene
is also hypermethylated in glioma cell lines and brain tumors
(Watanabe et al., 2010). Understanding the molecular function of
Zar proteins will help us understand their roles in early develop-
ment and in pathological conditions.Acknowledgements
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